Accessibility
Page map
Search
Contrast
Font size A- A A+

Publications

2022

  1. Przygodzka P, Soboska K, Sochacka E, Pacholczyk M, Braun M, Kassassir H, Papiewska-Pająk I, Kielbik M, Boncela J. Neuromedin U secreted by colorectal cancer cells promotes a tumour-supporting microenvironment. Cell Commun Signal 2022; 20(1):193. doi: 10.1186/s12964-022-01003-1.
  2. Szulc-Kielbik I, Klink M Polymorphonuclear Neutrophils and Tumors: Friend or Foe? Exp Suppl. 2022;113:141-167. doi: 10.1007/978-3-030-91311-3_5.
  3. Szulc-Kielbik I, Kielbik M. Tumor-Associated Macrophages: Reasons to Be Cheerful, Reasons to Be Fearful. Exp Suppl. 2022;113:107-140. doi: 10.1007/978-3-030-91311-3_4.
  4. Nowak M, Janas Ł, Soja M, Głowacka E, Szyłło K, Misiek M, Klink M. Chemokine expression in patients with ovarian cancer or benign ovarian tumors. Arch Med Sci 2022;18(3):682–689.
  5. Kielbik M, Szulc-Kielbik I, Klink M. E-Cadherin Expression in Relation to Clinicopathological Parameters and Survival of Patients with Epithelial Ovarian Cancer. Int J Mol Sci 2022; 23, 14383.

2021

  1. Kielbik M. Szulc-Kielbik I, Klink M. Calreticulin – multifunctional chaperone in immunogenic cell death. Potential significance as a prognostic biomarker in ovarian cancer patients. Cells 2021; 10(1): E130.
  2. Kielbik M. Szulc-Kielbik I, Klink M. Impact of Selected Signaling Proteins on SNAIL 1 and SNAIL 2 Expression in Ovarian Cancer Cell Lines in Relation to Cells’ Cisplatin Resistance and EMT Markers Level. Int J Mol Sci 2021; 22(2), 980.
  3. Szulc-Kielbik I, Kielbik M, Nowak M, Klink M. The implication of IL-6 in the invasiveness and chemoresistance of ovarian cancer cells. Systematic review of its potential role as a biomarker in ovarian cancer patients. Biochim Biophys Acta Rev Cancer 2021;1876(2):188639.
  4. Papiewska-Pająk I, Przygodzka P, Krzyżanowski D, Soboska K, Szulc-Kiełbik I, Stasikowska-Kanicka O, Boncela J, Wągrowska-Danilewicz M, Kowalska MA. Snail Overexpression Alters the microRNA Content of Extracellular Vesicles Released from HT29 Colorectal Cancer Cells and Activates Pro-Inflammatory State In Vivo. Cancers (Basel) 2021; 13(2): E172.

2020

  1. Nowak M, Klink M. The role of tumor‐associated macrophages in the progression and chemoresistance of ovarian cancer. Cells 2020; 9: 1299.
  2. Wilczynski M, Kielbik M, Senderowska D, Krawczyk T, Szymanska B, Klink M, Bieńkiewicz J, Romanowicz H, Frühauf F, Malinowski A. MiRNA-103/107 in Primary High-Grade Serous Ovarian Cancer and Its Clinical Significance. Cancers (Basel) 2020; 12: E2680.
  3. Szulc-Kielbik I, Brzostek A, Gatkowska J, Kielbik M, Klink M. Determination of in vitro and in vivo immune response to recombinant cholesterol oxidase from Mycobacterium tuberculosis. Immunol Lett 2020; 228: 103-111.

2019

  1. Kielbik M, Szulc-Kielbik I, Klink M. The potential role of iNOS in ovarian cancer progression and chemoresistance Int J Mol Sci 2019; 20 (7). pii: E1751. doi: 10.3390/ijms20071751.
  2. Szulc-Kielbik I, Kielbik M, Przygodzka P, Brzostek A, Dziadek J, Klink M. Mycobacterium tuberculosis requires cholesterol oxidase to disrupt TLR2 signalling in human macrophages. Mediators Inflamm 2019; 2019, ID 2373791.
  3. Kielbik M, Szulc-Kielbik I, Klink M. IRAK1 and IRAK4 signaling proteins are dispensable in the response of human neutrophils to Mycobacterium tuberculosis infection. FEMS Microbiol Lett 2019; 366(18). pii: fnz226.
  4. Bednarska-Szczepaniak K, Krzyżanowski D, Klink M, Nowak M. Adenosine analogues as opposite modulators of the cisplatin resistance of ovarian cancer cells. Anticancer Agents Med Chem 2019; 19: 473 – 486.

2018

  1. Nowak M, Głowacka E, Lewkowicz P, Banasik M, Szyłło K, Zimna K, Bednarska K, Klink M. Sub-optimal primary surgery leads to unfavorable immunological changes in ovarian cancer patients. Immunobiology 2018; 223: 1-7.
  2. Bednarska K, Król E, Glowacka E, Romanowicz H, Szyllo K, Klink M, Sulowska Z, Nowak M. Analysis of preoperative blood platelet parameters in terms of diversity of epithelial ovarian cancer. Medicine 2018; 97(12): e0180.
  3. Kielbik M, Krzyzanowski D, Pawlik B, Klink M. Cisplatin-induced ERK1/2 activity induces G1 to S phase progression results in chemoresistance of ovarian cancer cells. Oncotarget 2018; 9: 19847-19860.
  4. Bakuła Z, Brzostek A, Borówka P, Żaczek A, Szulc-Kiełbik I, Podpora A, Parniewski P, Strapagiel D, Dziadek J, Proboszcz M, Bielecki J, van Ingen J, Jagielski T. Molecular typing of Mycobacterium kansasii using pulsed-field gel electrophoresis and newly designed variable-number tandem repeat analysis. Scientific Reports 2018; 8: 4462.
›